by J. Gibson Pennington, MD, and Jeffrey Guina, MD From Wright-Patterson Air Force Base and Wright State University Boonshoft School of Medicine Department of Psychiatry, Dayton, Ohio Innov Clin Neurosci.
by Jonathan R. Scarff, MD Dr. Scarff is a staff psychiatrist at the Veterans Affairs Outpatient Clinic in Spartanburg, South Carolina, USA Innov Clin Neurosci. 2016;13(9–10):49–52 Funding: The author has
by Ann McNary, JD Ms. McNary is Senior Risk Manager at PRMS, Inc. in Arlington, Virginia. Innov Clin Neurosci. 2016;13(9–10)53–55. This ongoing column is dedicated to providing information to our
by Steven Lippmann, MD, and Malathi Latha Perugula, MD The authors are from the Department of Psychiatry and Behavioral Science, University of Louisville School of Medicine, Louisville, Kentucky. Innov Clin
Dear Colleagues: Welcome to the July–August 2016 issue of Innovations in Clinical Neuroscience. We start this issue with an interesting study by MacEwan et al titled, “Pharmaceutical Innovation in the
by Joanna P. MacEwan, PhD; Seth Seabury, PhD; Myrlene Sanon Aigbogun, MPH; Siddhesh Kamat, MS, MBA; Emma van Eijndhoven, MS, MA; Clement Francois, PhD; Crystal Henderson, PharmD, BCPP; and Leslie
by Jonathan R. Scarff, MD Dr. Scarff is with Veterans Affairs Outpatient Clinic, Spartanburg, South Carolina. Innov Clin Neurosci. 2016;13(7–8):26–29. Funding: No funding was received for the preparation of this
by Nazanin Arjomand Fard, MSci; Gholamreza Azizi, PhD; and Abbas Mirshafiey, PhD Dr. Fard is with Kish International Campus, University of Tehran, Tehran, Iran; Dr. Azizi is with Imam Hassan
by Ram S. Mahato, MD; Maria Chona P. San Gabriel, MD; Carrol T. Longshore, MD; and David B. Schnur, MD The authors are with the Department of Psychiatry at Elmhurst
by Donna Vanderpool, MBA, JD Ms. Vanderpool is Vice President of Risk Management at PRMS, Inc., Arlington, Virginia. Innov Clin Neurosci. 2016;13(7–8):41–44. This ongoing column is dedicated to providing information
by Malathi Latha Perugula, MD, and Steven Lippmann, MD The authors are from the Department of Psychiatry and Behavioral Science, University of Louisville School of Medicine, Louisville, Kentucky. Innov Clin
Innov Clin Neurosci. 2016;13(7–8):15–16. Dear Editor: Borderline personality disorder (BPD) is over-represented in prison populations, with 25 to 50 percent of incarcerated individuals suffering from this disorder.[1] As an empirical
Innov Clin Neurosci. 2016;13(7–8):13–14. Dear Editor: Substance use disorders frequently coexist with and complicate the treatment of mood and anxiety disorders. Gabapentin is one of the most commonly prescribed off-label
Dear Colleagues: Welcome to the May–June 2016 issue of Innovations in Clinical Neuroscience. I am pleased to start the issue with the first of a series of articles we’ll be
by Arshya Vahabzadeh, MD; Ned Sahin, PhD; and Amir Kalali, MD Dr. Vahabzadeh is Director of Digital Health, Brain Power, in Cambridge, Massachusetts; Instructor in Psychiatry, Harvard Medical School in
by Kimberly B. Mulcahy, PharmD; Eileen Trigoboff, RN, DNS; Lewis Opler, MD, PhD; and Tammie Lee Demler, BS, PharmD, MBA Drs. Trigoboff, Demler, and Mulcahy are with Buffalo Psychiatric Center,
by Masaru Nakamura, MD, PhD; Takahiko Nagamine, MD, PhD; Goro Sato, MD, PhD; and Kazue Besho, Phc Dr. Nakamura is with the Department of Psychiatric Internal Medicine, Kosekai-Kusatsu Hospital, Hiroshima,
by Ahmed Aboraya, MD, DrPh; Henry Nasrallah, MD; Srinivas Muvvala, MD, MPH; Ahmed El-Missiry, MD, MRCPsych, IFAPA; Hader Mansour, MD, PhD; Cheryl Hill, MD PhD; Daniel Elswick, MD; and Elizabeth
by Hena Jawaid, MB, BS, FCPS; Sana Younus, MB, BS; and Hanif Mesiya, MD All are with the Department of Psychiatry, Aga Khan University, Karachi, Pakistan. Innov Clin Neurosci. 2016;13(5–6):78–80.
by Ann McNary, JD Ms. McNary is a Senior Risk Manager with PRMS, Inc. Innov Clin Neurosci. 2016;13(5–6):81–82. This ongoing column is dedicated to providing information to our readers on